ClinicalTrials.gg
Active, not recruitingNCT05535933wAIHAUpdated May 18, 2026

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

A Phase 2/3 interventional study of HMPL-523(300mg PO QD) and Placebo in Warm Antibody Autoimmune Hemolytic Anemia, sponsored by Hutchmed. Active, not recruiting at 39 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Hutchmed · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Anemia, Hemolytic, Autoimmune with a site in China — 22 open to participants now, 30 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · China.

Enrollment
4th of 35
111 · median 18
Started
2022
with 1 other
Phase 2/3
2 of 39
none open now
Primary completion
2025-11
later than 7 of 29 live
Registered
9th of 39
by date

Among the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, this one is the 4th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 2/3, reaches primary completion later than 7 of the 29 other live ones, and was the 9th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

22 of the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, or all of them as a file.
02

Study summary

Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA.

Phase III Study(Part A): Confirmation of Efficacy safety and of HMPL-523 in adult patients with wAIHA.

Phase III Study (Part B): To further evaluate the long-term safety and tolerability of HMPL-523 in adult patients with wAIHA.

Read the detailed description

Phase II Study: An eight-week randomized, placebo-controlled, double-blind phase followed by at least a 16-week open-label HMPL-523 treatment to evaluate the safety and preliminary efficacy of HMPL-523. The primary endpoint was the proportion of patients with overall Hb response by week 24.

Phase III study (Part A):A 24-week randomized, placebo-controlled double-blind phase to evaluate efficacy and safety of HMPL-523. The primary endpoint was the proportion of patients who achieve a durable response during weeks 5 to 24.

Phase III Study (Part B): An open-label Phase evaluating long-term safety and efficacy of HMPL-523 treatment. Eligible patients include those with lack of efficacy during the 20-week Phase III Part A treatment, completion of the Phase II study, or completion of 24-week Phase III Part A treatment with investigators assessment of potential benefit from open-label treatment with HMPL-523.

03

Conditions studied

  • Warm Antibody Autoimmune Hemolytic Anemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed the form (ICF);
  2. Males or females aged 18 to 75 years;
  3. Patients diagnosed with primary wAIHA or secondary wAIHA whose underlying diseases are stable;
  4. Organs in good function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other types of AIHA other than wAIHA;
  2. Patients with secondary wAIHA with unstable underlying disease;
  3. Patients with drug-induced secondary wAIHA;
  4. Patients with infections requiring systemic treatment;
  5. Patients previously treated with Syk inhibitors (e.g., fostamatinib);
  6. Patients with known allergy to the active ingredients or of the study drug;
  7. Patients with serious psychological or mental disorder;
  8. Alcoholic or drug abuser;
  9. Female patients who are pregnant and lactating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    HMPL-523

    Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment. Phase III: Part A (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks. Part B (Open-label Phase): Eligible subjects will roll-over into the open-label phase and receive treatment with HMPL-523 at the same dose administered after 24-week randomized controlled trial phase (Part A) or in Phase II. Treatment will continue until 24 weeks after the last subject is enrolled in Part B.

    Drug: HMPL-523(300mg PO QD)

  • Placebo comparator
    Placebo

    Phase II: Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 8 weeks. Phase III: Part A (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 24 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Phase II: Overall Hb response rate

    Phase II: Overall Hb response rate: The proportion of patients with overall Hb response by Week 24

    Time frame: 24Weeks

  2. Phase III(Part A): Durable Hb response rate

    Phase III(Part A):Durable Hb response rate: The proportion of patients who achieve a durable response by Week 24 during Part A

    Time frame: 24Weeks

Secondary outcomes

  1. Phase II: Overall Hb response rate

    Phase II: Overall Hb response rate: the proportion of patients with overall Hb response by Week 8

    Time frame: 8 Weeks

  2. Phase II: Durable Hb response rate

    Phase II: Durable Hb response rate: the proportion of patients who achieve a durable response by Week 24.

    Time frame: 24 Weeks

  3. Phase II: Median change in Hb

    Phase II: Median change from baseline in Hb at Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  4. Phase II: Effects on reticulocyte count

    Phase II: Change from baseline in reticulocyte count at Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  5. Phase II: Effects on lactate dehydrogenase

    Phase II: Change from baseline in lactate dehydrogenase(LDH) at Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  6. Phase II: Effects on haptoglobin

    Phase II: Change from baseline in haptoglobin at Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  7. Phase II: Effects on total bilirubin(TBIL)

    Phase II: Change from baseline in total bilirubin(TBIL) at Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  8. Phase II: Proportion of rescue therapy

    Phase II: Proportion of patients who received rescue therapy by Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  9. Phase II: Proportion of patients with dose reduction in baseline anti-wAIHA medications

    Phase II: Proportion of patients who had a dose reduction in glucocorticoids or other baseline concomitant anti-wAIHA medications by Weeks 8 and 24 of treatment.

    Time frame: 24 Weeks

  10. Phase II: Time to response

    Phase II: Time to response

    Time frame: 24 Weeks

  11. Phase II: Effect of study treatment on patient fatigue

    Phase II: Evaluation of the effect of study treatment on fatigue at Weeks 8 and 24, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)

    Time frame: 24 Weeks

  12. Phase II: Effect of study treatment on quality of life

    Phase II: Evaluation of the effect of study treatment on quality of life at Weeks 8 and 24, as assessed by the 36-Item Short Form Health Survey (SF-36).

    Time frame: 24 Weeks

  13. Phase III(Part A): Overall Hb response rate

    Phase III(Part A): Proportion of patients who achieved an overall Hb response during the 20-week and 24-week double-blind treatment periods(defined as at least one Hb value ≥100g/L with an increase of at least 20g/L from baseline, not attributable to rescue therapy).

    Time frame: 24 Weeks

  14. Phase III(Part A): Median change in Hb

    Phase III(Part A): Median change from baseline in Hb during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  15. Phase III(Part A): Effects on reticulocyte count

    Phase III(Part A): Change from baseline in reticulocyte count during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  16. Phase III(Part A): Effects on lactate dehydrogenase

    Phase III(Part A): Change from baseline in lactate dehydrogenase(LDH) during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  17. Phase III(Part A): Effects on haptoglobin

    Phase III(Part A): Change from baseline in haptoglobin during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  18. Phase III(Part A): Effects on total bilirubin(TBIL)

    Phase III(Part A): Change from baseline in total bilirubin(TBIL) during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  19. Phase III(Part A): Proportion of rescue therapy

    Phase III(Part A): Proportion of patients who received protocol-defined rescue therapy during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  20. Phase III (Part A): Proportion of patients reducing or discontinuing baseline anti-wAIHA medications

    Phase III(Part A):The proportion of patients who reduced or discontinued glucocorticoids or other baseline concomitant anti-wAIHA medications during the 20-week and 24-week double-blind treatment periods.

    Time frame: 24 Weeks

  21. Phase III(Part A): Time to first response

    Phase III(Part A): Time to first response

    Time frame: 24 Weeks

  22. Phase III(Part A): Duration of durable response

    Phase III(Part A): Duration of durable response

    Time frame: 24 Weeks

  23. Phase III(Part A): Cumulative duration of response

    Phase III(Part A): Cumulative duration of response

    Time frame: 24 Weeks

  24. Phase III(Part A): Effect of study treatment on patient fatigue

    Phase III(Part A): Effect of study treatment on patient fatigue during the 20-week and 24-week treatment periods, as assessed by the FACIT-F score (40 items; range, 0-160), including the FACIT-Fatigue subscale (13 items; range, 0-52).

    Time frame: 24 Weeks

  25. Phase III(Part A): Effect of study treatment on patients' quality

    Phase III(Part A): Effect of study treatment on patients' quality of life during the 20-week and 24-week treatment periods, as assessed by SF-36.

    Time frame: 24 Weeks

Other outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs) assessed according to NCI CTCAE Version 5.0.

    Time frame: 36 Months

  2. Phase II:Efficacy in patients with DAT positivity confirmed by the central laboratory

    Phase II: Assessed by overall Hb response rate and durable response rate.

    Time frame: 24 Weeks

  3. Phase III(Part B): Durable Hb response rate

    Phase III(Part B): Durable Hb response rate: the proportion of patients who achieve a durable response during Part B.

    Time frame: 30 Months

07

Study locations

39 sites
08

References and documents

Publications

  • Zhao X, Sun J, Zhang Z, Chen M, Gong T, He G, Li Y, Liu H, Li F, Li X, Zhou H, Wang X, Hong M, Lei L, Yin H, Luo X, Li Y, Fan S, Guo X, Shi MM, Su W, Zhang L, Han B, Zhang F. Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. Lancet Haematol. 2025 Feb;12(2):e97-e108. doi: 10.1016/S2352-3026(24)00344-2. Epub 2025 Jan 9. PubMed 39799953 ↗

Individual participant data

Plan to share: Yes — The results of this study can be published in core journals or international scientific conferences, and the primary investigators who make significant contributions to the implementation and management of this study and the personnel who makes great contributions to the design, interpretation or analysis of this study (such as the staffs or consultants of the sponsor) can have their authorship attribution. The sponsor promises to provide the manuscript to the investigator for review before publication of any result of the study. Investigators have to obtain the approval of the sponsor before submitting academic articles or abstracts. The study personnel have the right to publish results of this study, however, the requirement of protecting confidential information must be met. The confidential information is the property of the sponsor only, cannot be disclosed to others without the written approval of the sponsor, and cannot be used for other purposes.

Supporting information: Study protocol, Informed consent form, Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Nov 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 10, 2022
StartActual
Sep 30, 2022
Primary completionActual
Nov 25, 2025
CompletionEst.
Nov 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05535933
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Sep 30, 2022
Primary completion
Nov 25, 2025
Completion
Nov 2026 (estimated)
Last update
May 18, 2026

Study contacts

Fengkui Zhang, professor
principal investigator · offices director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion